Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study

Background/Aims We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL). Methods Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for the study if their leukemic blast cells in bone...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Dong Won Baek, Han-Seung Park, Sang Kyun Sohn, Dae Young Kim, Inho Kim, Jae-Sook Ahn, Young Rok Do, Se Ryeon Lee, Hyeon-Seok Eom, Won-Sik Lee, Sung-Hyun Kim, Ho Sup Lee, Yoo Jin Lee, Joon Ho Moon, Je-Hwan Lee, Adult Acute Lymphoblastic Leukemia Working Party, the Korean Society of Hematology
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	The Korean Association of Internal Medicine 2023-09-01
Edice:	The Korean Journal of Internal Medicine
Témata:	survival leukemia acute lymphoblastic rituximab
On-line přístup:	http://kjim.org/upload/kjim-2022-401.pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!